The year in interventional cardiology

Journal of the American College of Cardiology

Volumn 45, Issue 7, 2005, Pages 1117-1134

  O'Neill, William W ^a   Dixon, Simon R ^a   Grines, Cindy L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HEXANOYLTAXOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DACTINOMYCIN; DEXAMETHASONE; ENOXAPARIN; ESTRADIOL; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FIBROBLAST GROWTH FACTOR 4; FOLIC ACID; HEPARIN; PACLITAXEL; PACLITAXEL DERIVATIVE; PRAVASTATIN; RAPAMYCIN; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; SIMVASTATIN; TENECTEPLASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACUTE HEART INFARCTION; ANEMIA; ANGINA PECTORIS; ANGIOGENESIS; ANGIOPLASTY; AORTA DISEASE; BETA ADRENERGIC RECEPTOR BLOCKING; BLEEDING; BLOOD CLOT LYSIS; BONE MARROW CELL; BRACHYTHERAPY; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; HEALTH CARE ORGANIZATION; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HIGH RISK PATIENT; HOSPITAL; HUMAN; IMAGE ANALYSIS; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KIDNEY DYSFUNCTION; MEDICAL INSTRUMENTATION; MEDICAL LITERATURE; MEDICAL PRACTICE; MORTALITY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REPERFUSION; RESTENOSIS; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL; THROMBOSIS;

EID: 15944364478     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.01.006     Document Type: Review

References (130)

1. E.M. Antman, D.T. Anbe, P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation 110 2004 588 636
2. A.G.C. Sutton, P.G. Campbell, R. Graham A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction (MERLIN) J Am Coll Cardiol 44 2004 287 296
3. C.L. Grines, W.W. O'Neill Rescue angioplasty: does the concept need to be rescued? J Am Coll Cardiol 44 2004 297 299
4. Gershlick A. Rescue angioplasty versus conservative treatment or repeat thrombolysis (REACT). Presented at: Annual Scientific Session of the American Heart Association, New Orleans, Louisiana, November 2004.
5. A. Schomig, G. Ndrepepa, J. Mehilli A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction J Am Coll Cardiol 44 2004 2073 2079
6. Le May MR. Combined angioplasty and pharmacological intervention versus thrombolytics alone in myocardial infarction (CAPITAL AMI). Presented at: Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 2004.
7. F. Fernandez-Aviles, J.J. Alonso, A. Castro-Beiras Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomized controlled trial Lancet 364 2004 1045 1053
8. A. Kastrati, J. Mehilli, K. Schlotterbeck Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention JAMA 291 2004 947 954
9. A.W.J. van't Hof, N. Ernst, M.J. de Boer Facilitation of primary coronary angioplasty by early start of a glycoprotein IIb/IIIa inhibitor: results of the Ongoing Tirofiban In Myocardial Infarction Evaluation (On-TIME) trial Eur Heart J 25 2004 837 846
10. T.P. Wharton, L.L. Grines, M.A. Turco Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI-No SOS Study) versus transfer to surgical centers for primary angioplasty J Am Coll Cardiol 43 2004 1943 1950
11. A. Kastrati, J. Mehilli, S. Nekolla A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy J Am Coll Cardiol 43 2004 734 741
12. H.M. Sadeghi, C.L. Grines, H.R. Chandra Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the CADILLAC trial) Am J Cardiol 94 2004 637 640
13. R.H. Mehta, K.J. Harjai, C.L. Grines Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes J Am Coll Cardiol 43 2004 1765 1772
14. S. Addala, C.L. Grines, S.R. Dixon Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score) Am J Cardiol 93 2004 629 632
15. P.S. Heggunje, K.J. Harjai, G.W. Stone Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction J Am Coll Cardiol 44 2004 1400 1407
16. G. Guagliumi, G.W. Stone, D.A. Cox Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial Circulation 110 2004 1598 1604
17. E. Nikolsky, E.D. Aymong, A. Halkin Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention J Am Coll Cardiol 44 2004 547 553
18. G.G. Pellizzon, C.L. Grines, D.A. Cox Importance of mitral regurgitation in patients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial J Am Coll Cardiol 43 2004 1368 1374
19. C.O. Costantini, G.W. Stone, R. Mehran Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction J Am Coll Cardiol 44 2004 305 312
20. M.G. McLaughlin, G.W. Stone, E. Aymong Prognostic utility of comparative methods for assessment of ST-resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial J Am Coll Cardiol 44 2004 1215 1223
21. G. Dangas, E.D. Aymong, R. Mehran Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial) Am J Cardiol 94 2004 983 988
22. Ali A. A prospective randomized controlled trial of thrombectomy with the AngioJet in acute myocardial infarction (AIMI). Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
23. Stone GW. Primary angioplasty in acute myocardial infarction with distal protection of the microcirculation: principal results from the prospective, randomized EMERALD trial. Presented at: Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 2004.
24. O'Neill WW. Acute myocardial infarction with hyperoxemic therapy (AMIHOT): a prospective, randomized, multicenter trial. Presented at: Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 2004.
25. Tzivoni D. Reduction of infarct size and improved left ventricular function with IV Caldaret (MCC-135) and primary percutaneous coronary intervention for ST elevation myocardial infarction. Presented at: Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 2004.
26. Mehta S, Diaz R, on behalf of the CREATE-ECLA Investigators. Clinical Trial of Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation-Estudios Cardiológicos Latinoamérica. Presented at: Annual Scientific Session of the American Heart Association, New Orleans, Louisiana, November 2004.
27. Grines CL. ICE-IT: Intravascular cooling adjunctive to percutaneous coronary intervention for acute myocardial infarction. Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
28. Siminiak T. Percutaneous transvenous transplantation of autologous myoblasts in the treatment of postinfarction heart failure: the POZNAN trial. Presented at: Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 2004.
29. Dib N, Kereiakes D, McCarthy P, et al. Long-term follow-up of safety and feasibility of autologous skeletal myoblast transplantation in patients undergoing coronary artery bypass graft surgery. Presented at: Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 2004.
30. K.C. Wollert, G.P. Meyer, J. Lotz Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial Lancet 364 2004 141 148
31. Fernandez-Aviles F. Intracoronary bone marrow cell transplantation after ST elevated myocardial infarction. Presented at: First International Conference on Cell Therapy for Cardiovascular Diseases, New York, June 2004.
32. F. Kuethe, B.M. Richartz, H.G. Sayer Lack of regeneration of myocardium by autologous intracoronary mononuclear bone marrow transplantation in humans with large anterior myocardial infarctions Int J Cardiol 97 2004 123 127
33. V. Schachinger, B. Assmus, M.B. Britten Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial J Am Coll Cardiol 44 2004 1690 1699
34. Y. Maekawa, T. Anzai, T. Yoshikawa Effected of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction J Am Coll Cardiol 44 2004 1510 1520
35. H.J. Kang, H.S. Kim, S.Y. Zhang Effects of intracoronary infusion of peripheral blood stem-cells mobilized with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC randomized trial Lancet 363; 2004 751 756
36. Nienaber C. Front integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor. Presented at: First International Conference on Cell Therapy for Cardiovascular Disease, New York, June 2004.
37. A. Halkin, C.L. Grines, D.A. Cox Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction J Am Coll Cardiol 43 2004 1780 1787
38. S.J. Kernis, K.J. Harjai, G.W. Stone Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 43 2004 1773 1779
39. B.K. Nallamothu, E.M. Antman, E.R. Bates Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment? Am J Cardiol 94 2004 772 774
40. PCAT-2 Collaborators E. Boersma, J. Simes, C. Grines, C. Westerhout Does time matter? Individual patient data-based meta-analysis of primary PCI versus fibrinolysis in acute myocardial infarction randomized trials Circulation 110 Suppl III 2004 III539
41. G. De Luca, A.W. van't Hof, M.J. de Boer Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty Eur Heart J 25 2004 1009 1013
42. G. De Luca, H. Suryapranata, J.P. Ottervanger, E.M. Antman Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction Circulation 109 2004 1223 1225
43. M.A. Saleem, H. Kannam, W.S. Aronow The effects of off-normal hours, age, and gender for coronary angioplasty on hospital mortality in patients undergoing coronary angioplasty for acute myocardial infarction Am J Cardiol 93 2004 763 764
44. E.H. Bradley, J. Herrin, Y. Wang Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction JAMA 292 2004 1563 1572
45. A.A. Bavry, D.J. Kumbhani, R. Quiroz Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature Am J Cardiol 93 2004 830 835
46. F.J. Neumann, A. Kastrati, G. Pogatsa-Murray Evaluation of prolonged antithrombotic pretreatment ('cooling off' strategy) before intervention in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 1593 1599
47. De Winter RJ. ICTUS: Invasive versus conservative treatment in unstable coronary syndromes. Presented at: European Society of Cardiology Congress 2004, Munich, Germany, August 2004.
48. M.A. Blazing, J.A. de Lemos, H.D. White Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin JAMA 292 2004 55 64
49. The SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
50. V.M.G. Legrand, P.W. Serruys, F. Unger Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease Circulation 109 2004 1114 1120
51. Serruys PW. A multicenter prospective registry of multivessel stenting with the polymer-based sirolimus-eluting stent--long-term results (ARTS-II). Presented at Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
52. P. Wahrborg, J.E. Booth, T. Clayton, the SoS Neuropsychology Substudy Investigators Neuropsychological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) trial Circulation 110 2004 3411 3417
53. M.F. Newman, J.L. Kirchner, B. Phillips-Bute Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery N Engl J Med 344 2001 395 402
54. R. Hambrecht, C. Walther, S. Mobius-Winkler Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial Circulation 109 2004 1371 1378
55. W. Hueb, P.R. Soares, B.J. Gersh The Medicine, Angioplasty, or Surgery Study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease J Am Coll Cardiol 43 2004 1743 1751
56. M. Pfisterer TIME Investigators Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME) Circulation 110 2004 1213 1218
57. E.L. Alderman, K.E. Kip, P.L. Whitlow Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI) J Am Coll Cardiol 44 2004 766 774
58. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
59. D.E. Wennberg, F.L. Lucas, A.E. Siewers, M.A. Kellett, D.J. Malenka Outcomes of percutaneous coronary interventions performed at centers without and with onsite coronary artery bypass graft surgery JAMA 292 2004 1961 1968
60. A. Epstein, S.S. Rathore, K.G.M. Volpp, H.M. Krumholz Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000 J Am Coll Cardiol 43 2004 1755 1762
61. M. Singh, C.S. Rihal, R.J. Lennon, K.N. Garratt, D.R. Holmes Jr Comparison of Mayo Clinic risk score and American College of Cardiology/American Heart Association lesion classification in the prediction of adverse cardiovascular outcome following percutaneous coronary interventions J Am Coll Cardiol 44 2004 357 361
62. G. Marenzi, G. Lauri, E. Assanelli Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction J Am Coll Cardiol 44 2004 1780 1785
63. R. Mehran, E.D. Aymong, E. Nikolsky A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation J Am Coll Cardiol 44 2004 1393 1399
64. B.A. Bartholomew, K.J. Harjai, S. Dukkipati Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification Am J Cardiol 93 2004 1515 1519
65. A. Norhammar, K. Malmberg, E. Diderholm Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization J Am Coll Cardiol 43 2004 585 591
66. E. Nikolsky, R. Mehran, D. Turcot Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention Am J Cardiol 94 2004 300 305
67. R.A. Corpus, P.B. George, J.A. House Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention J Am Coll Cardiol 43 2004 8 14
68. R.M. Minutello, E.T. Chou, M.K. Hong Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry) Am J Cardiol 93 2004 1229 1232
69. P.C. Lee, A.S. Kini, C. Ahsan, E. Fisher, S.K. Sharma Anemia is an independent predictor of mortality after percutaneous coronary intervention J Am Coll Cardiol 44 2004 541 546
70. R.S. McKechnie, D. Smith, C. Montoye Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention Circulation 110 2004 271 277
71. S.V. Rao, J.G. Jollis, R.A. Harrington Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562
72. Henry TD. A multicenter prospective randomized trial of intracoronary administration of Ad.FGF-4 in patients with no revascularization options (AGENT-3). Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
73. E.C. Perin, H.F.R. Dohmann, R. Borojevic Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy Circulation 110 Suppl II 2004 II213 II218
74. E. Grube, S. Sonoda, F. Ikeno Six and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer Circulation 109 2004 2168 2171
75. A. Gershlick, I. De Scheerder, B. Chevalier Inhibition of restenosis with a paclitaxel-eluting polymer-free coronary stent Circulation 109 2004 487 493
76. A.J. Lansky, R.A. Costa, G.S. Mintz Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial Circulation 109 2004 1948 1954
77. R. Hoffmann, R. Langenberg, P. Radke Evaluation of a high-dose dexamethasone-eluting stent Am J Cardiol 94 2004 193 195
78. A. Abizaid, M. Albertal, M.A. Costa First human experience with the 17-beta-estradiol-eluting stent J Am Coll Cardiol 43 2004 1118 1121
79. P.W. Serruys, J.A. Ormiston, G. Sianos Actinomycin-eluting stent for coronary revascularization J Am Coll Cardiol 44 2004 1363 1367
80. E. Grube, A. Lansky, K.E. Hauptmann High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization J Am Coll Cardiol 44 2004 1368 1372
81. G.W. Stone, S.G. Ellis, D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
82. G.W. Stone, S.G. Ellis, D.A. Cox One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting Taxus stent Circulation 109 2004 1942 1947
83. D.R. Holmes, M.B. Leon, J.W. Moses Analysis of 1-year clinical outcomes in the SIRIUS trial Circulation 109 2004 634 640
84. I. Moussa, M.B. Leon, D.S. Baim Impact of sirolimus-eluting stents on outcome in diabetic patients Circulation 109 2004 2273 2278
85. N. Sawhney, J.W. Moses, M.B. Leon Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents Circulation 110 2004 374 379
86. P.A. Lemos, P.W. Serruys, R.T. van Domburg Unrestricted utilization of sirolimus-eluting stents compared with conventional bare metal stent implantation in the 'real world ' Circulation 109 2004 190 195
87. M. Degertekin, C.A. Arampatzis, P.A. Lemos Very long sirolimus-eluting stent implantation for de novo coronary lesions Am J Cardiol 93 2004 826 829
88. Park SJ. Long DES: multicenter prospective registry study for DES implantation in long coronary lesion. Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
89. E. Schampaert, E.A. Cohen, M. Schluter The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) J Am Coll Cardiol 43 2004 1110 1115
90. A. Hoye, K. Tanabe, P.A. Lemos Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions J Am Coll Cardiol 43 2004 1954 1958
91. G.S. Werner, A. Krack, G. Schwarz, D. Prochnau, S. Betge, H.R. Figulla Prevention of lesion recurrence in chronic total occlusions by paclitaxel-eluting stents J Am Coll Cardiol 44 2004 2301 2306
92. A. Hoye, P.A. Lemos, C.A. Arampatzis Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease J Invasive Cardiol 16 2004 230 233
93. P.A. Lemos, F. Saia, S.H. Hofma Short and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction J Am Coll Cardiol 43 2004 704 708
94. I. Iakovou, L. Ge, I. Michev Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions J Am Coll Cardiol 44 2004 967 971
95. D. Orlic, E. Bonizzoni, G. Stankovic Treatment of multivessel coronary artery disease with sirolimus-eluting stents implantation: immediate and mid-term results J Am Coll Cardiol 43 2004 1154 1160
96. J.S. de Lezo, A. Medina, M. Pan Rapamycin-eluting stents for the treatment of unprotected left main disease Am Heart J 148 2004 481 485
97. C.A. Arampatzis, P.A. Lemos, A. Hoye Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and year clinical outcome Cathet Cardiovasc Interv 62 2004 292 296
98. D. Ardissino, C. Cavallini, E. Bramucci Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial JAMA 292 2004 2727 2734
99. A. Colombo, J.W. Moses, M.C. Morice Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions Circulation 109 2004 1244 1249
100. Kastrati A. Intracoronary stenting and antithrombotic regimen: drug-eluting stents for in-stent restenosis (ISAR-DESIRE). Presented at: European Society of Cardiology, Munich, Germany, 2004.
101. P.A. Lemos, A. Hoye, D. Goedhart Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients Circulation 109 2004 1366 1370
102. P.A. Lemos, C.A.G. van Mieghem, C.A. Arampatzis Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes Circulation 109 2004 2500 2502
103. E. Regar, P.A. Lemos, F. Saia Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients Am J Cardiol 93 2004 1271 1275
104. A. Jeremias, B. Sylvia, J. Bridges Stent thrombosis after successful sirolimus-eluting stent implantation Circulation 109 2004 1930 1932
105. E.P. McFadden, E. Stabile, E. Regar Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 2004 1519 1521
106. R. Albiero, S. Silber, C. Di Mario Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis J Am Coll Cardiol 43 2004 943 949
107. P.W. Serruys, W. Wijns, G. Sianos Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term antiplatelet treatment J Am Coll Cardiol 44 2004 528 537
108. M. Sabate, G. Pimentel, C. Prieto Intracoronary brachytherapy after stenting de novo lesions in diabetic patients J Am Coll Cardiol 44 2004 520 527
109. H.P. Bestehorn, F.J. Neumann, H.J. Buttner Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention (VESPA) J Am Coll Cardiol 43 2004 2160 2165
110. J. Hausleiter, A. Kastrati, J. Mehilli Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis (OSIRIS) Circulation 110 2004 790 795
111. R. Waksman, A.E. Ajani, A.D. Pichard Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions J Am Coll Cardiol 44 2004 1386 1392
112. H. Lange, H. Suryapranata, G. De Luca Folate therapy and in-stent restenosis after coronary stenting N Engl J Med 350 2004 2673 2681
113. Carrozza JP. A prospective randomized controlled trial of distal protection with the Kensey-Nash TriActiv system compared to the GuardWire or FilterWire (PRIDE). Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
114. Holmes DR. A prospective randomized controlled of distal protection with the third generation MedNova EmboShield compared to the GuardWire or FilterWire (CAPTIVE). Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
115. Buchbinder M. A prospective randomized trial of a PTFE self-expanding stent graft during saphenous vein graft intervention--late results (SYMBIOT III). Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
116. J.S. Yadav, M.H. Wholey, R.E. Kuntz Protected carotid-artery stenting versus endarterectomy in high-risk patients N Engl J Med 351 2004 1493 1501
117. Gray WA. Final composite endpoint results for the Archer study one-year results: Acculink for Revascularization of Carotids in High-Risk patients. Presented at: Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 2004.
118. Ramee SR. MAVERICK II: a prospective registry of carotid stenting with the Exponent stent and distal protection with the GuardWire in high risk patients. Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
119. Hopkins LN. CABERNET: a prospective registry of carotid stenting with the Nexstent and distal protection with the FilterWire EX in high risk patients. Presented at: Transcatheter Cardiovascular Therapeutics 2004, Washington, DC, September 2004.
120. M. Prinssen, E.L.G. Verhoeven, J. Buth A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms N Engl J Med 351 2004 1607 1618
121. E.O. McFalls, H.B. Ward, T.E. Moritz Coronary artery revascularization before elective major vascular surgery N Engl J Med 351 2004 2795 2804
122. A. Kastrati, J. Mehilli, H. Schuhlen A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel N Engl J Med 350 2004 232 238
123. J. Mehilli, A. Kastrati, H. Schuhlen Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel Circulation 110 2004 3627 3635
124. W.H. Chen, P.Y. Lee, W. Ng Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J Am Coll Cardiol 43 2004 1122 1126
125. S. Matetzky, B. Shenkman, V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
126. D.E. Kandzari, V. Hasselblad, J.E. Tcheng Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials Am Heart J 147 2004 457 462
127. J.P. Dery, G.A. Braden, M. Lincoff Final results of the Reopro Readministration Registry Am J Cardiol 93 2004 979 984
128. A.M. Lincoff, N.S. Kleiman, D.J. Kereiakes Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention JAMA 292 2004 696 703
129. G.J. Merten, W.P. Burgess, L.V. Gray Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial JAMA 291 2004 2328 2334
130. K. Spargias, E. Alexopoulos, S. Kyrzopoulos Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention Circulation 110 2004 2837 2842